The BAFF- and a proliferation-inducing ligand (APRIL)-neutralizing atacicept also reduces B cell counts in patients with SLE, underscoring the versatility of options in modulating this pathway [29, 38]. Here, TNFSF13 is linked to systemic lupus erythematosus.